PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ

• Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk …

Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL

• The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocy…

While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW

• Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus …

Abst0327 #ACR22 SMART-SLE Monitoring Some SLE patients with +dsDNA have persistent positivity, others have fluctuations Anti-dsDNA in persistently positive HR 1.56 for flare risk Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43 @RheumNow https://t.co/YwDPTYWPLu

Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE

Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx